Global Veterinary Vaccine
Global Veterinary Vaccine

Veterinary Vaccine Comprehensive Study by Type (Livestock Vaccines {Bovine Vaccines, Poultry Vaccines, Porcine Vaccines, Others}, Companion Animal Vaccines {Canine Vaccines, Feline Vaccines, Equine Vaccines}), Technology (Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Others) Players and Region - Global Market Outlook to 2024

Veterinary Vaccine Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024 | CAGR: 5.9%  

Aug 2019 Edition 225 Pages 220 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Veterinary Vaccine Market Overview:
Vaccines employed for the prevention of several diseases that affect animals can be grouped under veterinary vaccines. These vaccines are an important arrow in the quiver of the veterinarian and are arguably one of the most powerful tools in keeping animals healthy and well. They also have an impact on human health by ensuring safe food supplies and preventing animal-to-human transmission of infectious diseases. Also, these vaccines be an efficient tool in reducing the need to use antibiotics in animals, thereby contributing to the fight against antimicrobial resistance. Recent advances in technologies and improved understanding of pathogenicity, immunology, and epidemiology have opened new opportunities for preventing infectious diseases at an unprecedented level. According to AMA, the Global Veterinary Vaccine market is expected to see growth rate of 5.9%

Market Drivers
  • Increasing Incidence of Livestock Diseases
  • Increasing Incidence of Zoonotic Diseases
  • Initiatives by Government Agencies and Animal Associations


Restraints
  • High Storage Costs for Vaccines
  • Shortage of Veterinarians and Skilled Farm Workers

Opportunities
  • Recent Advancements in Technologies
  • Improved Understanding of Pathogenicity, Immunology and Epidemiology Have Opened New Opportunities

Challenges
  • Infectious & Bacterial Diseases Remain a Major Challenge


Competitive Landscape:

Some of the key players profiled in the report are Zoetis Animal Healthcare (United States), Merck & Co. (United States), Virbac SA (France), Hester Biosciences Ltd (India), Elanco (United States), Boehringer Ingelheim Animal Health GmbH (Germany), Ceva Sante Animale (France), Phibro Animal Health Corp. (United States), HIPRA (Spain) and MVP Laboratories Inc. (United States). Additionally, following companies can also be profiled that are part of our coverage like QianYuanHao Biological Corporation Limited (China), IZO S.r.l. (Italy), Intervet International BV (Netherlands) and Indian Immunologicals Limited (India). Analyst at AdvanceMarketAnalytics see United States Vendors to retain maximum share of Global Veterinary Vaccine market by 2024. Considering Market by Technology, the sub-segment i.e. Live Attenuated Vaccines will boost the Veterinary Vaccine market.

Market Highlights:
On 17 May 2019, Ceva Santé Animale (“Ceva”) and IDT Biologika GmbH have reached a provisional agreement for Ceva to acquire IDT’s veterinary biopharmaceutical portfolio and R&D activities, allowing IDT to focus on the manufacture of human biotechnology vaccines and pharmaceuticals for national and international markets. and On 26 April 2019, Elanco Animal Health has announced it has signed an agreement to acquire Aratana Therapeutics, a pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats, and developer of the first-of-its-kind canine NSAID for osteoarthritis, Galliprant. Elanco has also signed a development and commercialization agreement with VetDC for Tanovea-CA1, the first U.S. Food and Drug Administration (FDA) conditionally approved canine lymphoma treatment.

On 24 Jan. 2019, Boehringer Ingelheim, the world’s leading animal health company, announced that swine vaccine Ingelvac®PRRS MLV, produced by its veterinary vaccine manufacturing plant in the China Medical City in Taizhou, Jiangsu Province, is now officially supplied to the China market. Shifting imported vaccines to locally-produced vaccines will help significantly shorten the interval between the plant and animal farms. and On 12 Oct. 2018 – Boehringer Ingelheim has inaugurated its new global center for biological research and development at its Lyon Porte-des-Alpes (LPA) location in Saint-Priest France. With this 70 million euro investment, the German group signals its intention to reinforce its leading position in the veterinary vaccine market by bringing its R&D and biological production activities into the same center of excellence.

APHIS regulates veterinary biologics (vaccines, bacterins, antisera, diagnostic kits, and other products of biological origin) to ensure that the veterinary biologics available for the diagnosis, prevention, and treatment of animal diseases are pure, safe, potent, and effective. This work is done by APHIS Center for Veterinary Biologics (CVB) and is centered around enforcement of the Virus Serum Toxin Act.

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Veterinary Vaccine market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Veterinary Vaccine market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Veterinary Vaccine Manufacturers, Veterinary Vaccine Raw Material Suppliers, Veterinary Vaccine Traders/Distributors, Veterinary Vaccine Importer/Exporter, Technology Investors, Government Research Institutes and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • Livestock Vaccines {Bovine Vaccines, Poultry Vaccines, Porcine Vaccines, Others}
  • Companion Animal Vaccines {Canine Vaccines, Feline Vaccines, Equine Vaccines}
By Technology
  • Live Attenuated Vaccines
  • Inactivated Vaccines
  • Toxoid Vaccines
  • Recombinant Vaccines
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Incidence of Livestock Diseases
      • 3.2.2. Increasing Incidence of Zoonotic Diseases
      • 3.2.3. Initiatives by Government Agencies and Animal Associations
    • 3.3. Market Challenges
      • 3.3.1. Infectious & Bacterial Diseases Remain a Major Challenge
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Veterinary Vaccine, by Type, Technology and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Veterinary Vaccine (Value)
      • 5.2.1. Global Veterinary Vaccine by: Type (Value)
        • 5.2.1.1. Livestock Vaccines {Bovine Vaccines, Poultry Vaccines, Porcine Vaccines, Others}
        • 5.2.1.2. Companion Animal Vaccines {Canine Vaccines, Feline Vaccines, Equine Vaccines}
      • 5.2.2. Global Veterinary Vaccine by: Technology (Value)
        • 5.2.2.1. Live Attenuated Vaccines
        • 5.2.2.2. Inactivated Vaccines
        • 5.2.2.3. Toxoid Vaccines
        • 5.2.2.4. Recombinant Vaccines
        • 5.2.2.5. Others
      • 5.2.3. Global Veterinary Vaccine Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Veterinary Vaccine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Zoetis Animal Healthcare (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck & Co. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Virbac SA (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Hester Biosciences Ltd (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Elanco (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Boehringer Ingelheim Animal Health GmbH (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Ceva Sante Animale (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Phibro Animal Health Corp. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. HIPRA (Spain)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. MVP Laboratories Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Veterinary Vaccine Sale, by Type, Technology and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Veterinary Vaccine (Value)
      • 7.2.1. Global Veterinary Vaccine by: Type (Value)
        • 7.2.1.1. Livestock Vaccines {Bovine Vaccines, Poultry Vaccines, Porcine Vaccines, Others}
        • 7.2.1.2. Companion Animal Vaccines {Canine Vaccines, Feline Vaccines, Equine Vaccines}
      • 7.2.2. Global Veterinary Vaccine by: Technology (Value)
        • 7.2.2.1. Live Attenuated Vaccines
        • 7.2.2.2. Inactivated Vaccines
        • 7.2.2.3. Toxoid Vaccines
        • 7.2.2.4. Recombinant Vaccines
        • 7.2.2.5. Others
      • 7.2.3. Global Veterinary Vaccine Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Veterinary Vaccine: by Type(USD Million)
  • Table 2. Veterinary Vaccine Livestock Vaccines {Bovine Vaccines, Poultry Vaccines, Porcine Vaccines, Others} , by Region USD Million (2013-2018)
  • Table 3. Veterinary Vaccine Companion Animal Vaccines {Canine Vaccines, Feline Vaccines, Equine Vaccines} , by Region USD Million (2013-2018)
  • Table 4. Veterinary Vaccine: by Technology(USD Million)
  • Table 5. Veterinary Vaccine Live Attenuated Vaccines , by Region USD Million (2013-2018)
  • Table 6. Veterinary Vaccine Inactivated Vaccines , by Region USD Million (2013-2018)
  • Table 7. Veterinary Vaccine Toxoid Vaccines , by Region USD Million (2013-2018)
  • Table 8. Veterinary Vaccine Recombinant Vaccines , by Region USD Million (2013-2018)
  • Table 9. Veterinary Vaccine Others , by Region USD Million (2013-2018)
  • Table 10. South America Veterinary Vaccine, by Country USD Million (2013-2018)
  • Table 11. South America Veterinary Vaccine, by Type USD Million (2013-2018)
  • Table 12. South America Veterinary Vaccine, by Technology USD Million (2013-2018)
  • Table 13. Brazil Veterinary Vaccine, by Type USD Million (2013-2018)
  • Table 14. Brazil Veterinary Vaccine, by Technology USD Million (2013-2018)
  • Table 15. Argentina Veterinary Vaccine, by Type USD Million (2013-2018)
  • Table 16. Argentina Veterinary Vaccine, by Technology USD Million (2013-2018)
  • Table 17. Rest of South America Veterinary Vaccine, by Type USD Million (2013-2018)
  • Table 18. Rest of South America Veterinary Vaccine, by Technology USD Million (2013-2018)
  • Table 19. Asia Pacific Veterinary Vaccine, by Country USD Million (2013-2018)
  • Table 20. Asia Pacific Veterinary Vaccine, by Type USD Million (2013-2018)
  • Table 21. Asia Pacific Veterinary Vaccine, by Technology USD Million (2013-2018)
  • Table 22. China Veterinary Vaccine, by Type USD Million (2013-2018)
  • Table 23. China Veterinary Vaccine, by Technology USD Million (2013-2018)
  • Table 24. Japan Veterinary Vaccine, by Type USD Million (2013-2018)
  • Table 25. Japan Veterinary Vaccine, by Technology USD Million (2013-2018)
  • Table 26. India Veterinary Vaccine, by Type USD Million (2013-2018)
  • Table 27. India Veterinary Vaccine, by Technology USD Million (2013-2018)
  • Table 28. South Korea Veterinary Vaccine, by Type USD Million (2013-2018)
  • Table 29. South Korea Veterinary Vaccine, by Technology USD Million (2013-2018)
  • Table 30. Taiwan Veterinary Vaccine, by Type USD Million (2013-2018)
  • Table 31. Taiwan Veterinary Vaccine, by Technology USD Million (2013-2018)
  • Table 32. Australia Veterinary Vaccine, by Type USD Million (2013-2018)
  • Table 33. Australia Veterinary Vaccine, by Technology USD Million (2013-2018)
  • Table 34. Rest of Asia-Pacific Veterinary Vaccine, by Type USD Million (2013-2018)
  • Table 35. Rest of Asia-Pacific Veterinary Vaccine, by Technology USD Million (2013-2018)
  • Table 36. Europe Veterinary Vaccine, by Country USD Million (2013-2018)
  • Table 37. Europe Veterinary Vaccine, by Type USD Million (2013-2018)
  • Table 38. Europe Veterinary Vaccine, by Technology USD Million (2013-2018)
  • Table 39. Germany Veterinary Vaccine, by Type USD Million (2013-2018)
  • Table 40. Germany Veterinary Vaccine, by Technology USD Million (2013-2018)
  • Table 41. France Veterinary Vaccine, by Type USD Million (2013-2018)
  • Table 42. France Veterinary Vaccine, by Technology USD Million (2013-2018)
  • Table 43. Italy Veterinary Vaccine, by Type USD Million (2013-2018)
  • Table 44. Italy Veterinary Vaccine, by Technology USD Million (2013-2018)
  • Table 45. United Kingdom Veterinary Vaccine, by Type USD Million (2013-2018)
  • Table 46. United Kingdom Veterinary Vaccine, by Technology USD Million (2013-2018)
  • Table 47. Netherlands Veterinary Vaccine, by Type USD Million (2013-2018)
  • Table 48. Netherlands Veterinary Vaccine, by Technology USD Million (2013-2018)
  • Table 49. Rest of Europe Veterinary Vaccine, by Type USD Million (2013-2018)
  • Table 50. Rest of Europe Veterinary Vaccine, by Technology USD Million (2013-2018)
  • Table 51. MEA Veterinary Vaccine, by Country USD Million (2013-2018)
  • Table 52. MEA Veterinary Vaccine, by Type USD Million (2013-2018)
  • Table 53. MEA Veterinary Vaccine, by Technology USD Million (2013-2018)
  • Table 54. Middle East Veterinary Vaccine, by Type USD Million (2013-2018)
  • Table 55. Middle East Veterinary Vaccine, by Technology USD Million (2013-2018)
  • Table 56. Africa Veterinary Vaccine, by Type USD Million (2013-2018)
  • Table 57. Africa Veterinary Vaccine, by Technology USD Million (2013-2018)
  • Table 58. North America Veterinary Vaccine, by Country USD Million (2013-2018)
  • Table 59. North America Veterinary Vaccine, by Type USD Million (2013-2018)
  • Table 60. North America Veterinary Vaccine, by Technology USD Million (2013-2018)
  • Table 61. United States Veterinary Vaccine, by Type USD Million (2013-2018)
  • Table 62. United States Veterinary Vaccine, by Technology USD Million (2013-2018)
  • Table 63. Canada Veterinary Vaccine, by Type USD Million (2013-2018)
  • Table 64. Canada Veterinary Vaccine, by Technology USD Million (2013-2018)
  • Table 65. Mexico Veterinary Vaccine, by Type USD Million (2013-2018)
  • Table 66. Mexico Veterinary Vaccine, by Technology USD Million (2013-2018)
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Veterinary Vaccine: by Type(USD Million)
  • Table 78. Veterinary Vaccine Livestock Vaccines {Bovine Vaccines, Poultry Vaccines, Porcine Vaccines, Others} , by Region USD Million (2019-2024)
  • Table 79. Veterinary Vaccine Companion Animal Vaccines {Canine Vaccines, Feline Vaccines, Equine Vaccines} , by Region USD Million (2019-2024)
  • Table 80. Veterinary Vaccine: by Technology(USD Million)
  • Table 81. Veterinary Vaccine Live Attenuated Vaccines , by Region USD Million (2019-2024)
  • Table 82. Veterinary Vaccine Inactivated Vaccines , by Region USD Million (2019-2024)
  • Table 83. Veterinary Vaccine Toxoid Vaccines , by Region USD Million (2019-2024)
  • Table 84. Veterinary Vaccine Recombinant Vaccines , by Region USD Million (2019-2024)
  • Table 85. Veterinary Vaccine Others , by Region USD Million (2019-2024)
  • Table 86. South America Veterinary Vaccine, by Country USD Million (2019-2024)
  • Table 87. South America Veterinary Vaccine, by Type USD Million (2019-2024)
  • Table 88. South America Veterinary Vaccine, by Technology USD Million (2019-2024)
  • Table 89. Brazil Veterinary Vaccine, by Type USD Million (2019-2024)
  • Table 90. Brazil Veterinary Vaccine, by Technology USD Million (2019-2024)
  • Table 91. Argentina Veterinary Vaccine, by Type USD Million (2019-2024)
  • Table 92. Argentina Veterinary Vaccine, by Technology USD Million (2019-2024)
  • Table 93. Rest of South America Veterinary Vaccine, by Type USD Million (2019-2024)
  • Table 94. Rest of South America Veterinary Vaccine, by Technology USD Million (2019-2024)
  • Table 95. Asia Pacific Veterinary Vaccine, by Country USD Million (2019-2024)
  • Table 96. Asia Pacific Veterinary Vaccine, by Type USD Million (2019-2024)
  • Table 97. Asia Pacific Veterinary Vaccine, by Technology USD Million (2019-2024)
  • Table 98. China Veterinary Vaccine, by Type USD Million (2019-2024)
  • Table 99. China Veterinary Vaccine, by Technology USD Million (2019-2024)
  • Table 100. Japan Veterinary Vaccine, by Type USD Million (2019-2024)
  • Table 101. Japan Veterinary Vaccine, by Technology USD Million (2019-2024)
  • Table 102. India Veterinary Vaccine, by Type USD Million (2019-2024)
  • Table 103. India Veterinary Vaccine, by Technology USD Million (2019-2024)
  • Table 104. South Korea Veterinary Vaccine, by Type USD Million (2019-2024)
  • Table 105. South Korea Veterinary Vaccine, by Technology USD Million (2019-2024)
  • Table 106. Taiwan Veterinary Vaccine, by Type USD Million (2019-2024)
  • Table 107. Taiwan Veterinary Vaccine, by Technology USD Million (2019-2024)
  • Table 108. Australia Veterinary Vaccine, by Type USD Million (2019-2024)
  • Table 109. Australia Veterinary Vaccine, by Technology USD Million (2019-2024)
  • Table 110. Rest of Asia-Pacific Veterinary Vaccine, by Type USD Million (2019-2024)
  • Table 111. Rest of Asia-Pacific Veterinary Vaccine, by Technology USD Million (2019-2024)
  • Table 112. Europe Veterinary Vaccine, by Country USD Million (2019-2024)
  • Table 113. Europe Veterinary Vaccine, by Type USD Million (2019-2024)
  • Table 114. Europe Veterinary Vaccine, by Technology USD Million (2019-2024)
  • Table 115. Germany Veterinary Vaccine, by Type USD Million (2019-2024)
  • Table 116. Germany Veterinary Vaccine, by Technology USD Million (2019-2024)
  • Table 117. France Veterinary Vaccine, by Type USD Million (2019-2024)
  • Table 118. France Veterinary Vaccine, by Technology USD Million (2019-2024)
  • Table 119. Italy Veterinary Vaccine, by Type USD Million (2019-2024)
  • Table 120. Italy Veterinary Vaccine, by Technology USD Million (2019-2024)
  • Table 121. United Kingdom Veterinary Vaccine, by Type USD Million (2019-2024)
  • Table 122. United Kingdom Veterinary Vaccine, by Technology USD Million (2019-2024)
  • Table 123. Netherlands Veterinary Vaccine, by Type USD Million (2019-2024)
  • Table 124. Netherlands Veterinary Vaccine, by Technology USD Million (2019-2024)
  • Table 125. Rest of Europe Veterinary Vaccine, by Type USD Million (2019-2024)
  • Table 126. Rest of Europe Veterinary Vaccine, by Technology USD Million (2019-2024)
  • Table 127. MEA Veterinary Vaccine, by Country USD Million (2019-2024)
  • Table 128. MEA Veterinary Vaccine, by Type USD Million (2019-2024)
  • Table 129. MEA Veterinary Vaccine, by Technology USD Million (2019-2024)
  • Table 130. Middle East Veterinary Vaccine, by Type USD Million (2019-2024)
  • Table 131. Middle East Veterinary Vaccine, by Technology USD Million (2019-2024)
  • Table 132. Africa Veterinary Vaccine, by Type USD Million (2019-2024)
  • Table 133. Africa Veterinary Vaccine, by Technology USD Million (2019-2024)
  • Table 134. North America Veterinary Vaccine, by Country USD Million (2019-2024)
  • Table 135. North America Veterinary Vaccine, by Type USD Million (2019-2024)
  • Table 136. North America Veterinary Vaccine, by Technology USD Million (2019-2024)
  • Table 137. United States Veterinary Vaccine, by Type USD Million (2019-2024)
  • Table 138. United States Veterinary Vaccine, by Technology USD Million (2019-2024)
  • Table 139. Canada Veterinary Vaccine, by Type USD Million (2019-2024)
  • Table 140. Canada Veterinary Vaccine, by Technology USD Million (2019-2024)
  • Table 141. Mexico Veterinary Vaccine, by Type USD Million (2019-2024)
  • Table 142. Mexico Veterinary Vaccine, by Technology USD Million (2019-2024)
  • Table 143. Research Programs/Design for This Report
  • Table 144. Key Data Information from Secondary Sources
  • Table 145. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Veterinary Vaccine: by Type USD Million (2013-2018)
  • Figure 5. Global Veterinary Vaccine: by Technology USD Million (2013-2018)
  • Figure 6. South America Veterinary Vaccine Share (%), by Country
  • Figure 7. Asia Pacific Veterinary Vaccine Share (%), by Country
  • Figure 8. Europe Veterinary Vaccine Share (%), by Country
  • Figure 9. MEA Veterinary Vaccine Share (%), by Country
  • Figure 10. North America Veterinary Vaccine Share (%), by Country
  • Figure 11. Global Veterinary Vaccine share by Players 2018 (%)
  • Figure 12. Global Veterinary Vaccine share by Players (Top 3) 2018(%)
  • Figure 13. Global Veterinary Vaccine share by Players (Top 5) 2018(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Zoetis Animal Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 16. Zoetis Animal Healthcare (United States) Revenue: by Geography 2018
  • Figure 17. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Merck & Co. (United States) Revenue: by Geography 2018
  • Figure 19. Virbac SA (France) Revenue, Net Income and Gross profit
  • Figure 20. Virbac SA (France) Revenue: by Geography 2018
  • Figure 21. Hester Biosciences Ltd (India) Revenue, Net Income and Gross profit
  • Figure 22. Hester Biosciences Ltd (India) Revenue: by Geography 2018
  • Figure 23. Elanco (United States) Revenue, Net Income and Gross profit
  • Figure 24. Elanco (United States) Revenue: by Geography 2018
  • Figure 25. Boehringer Ingelheim Animal Health GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 26. Boehringer Ingelheim Animal Health GmbH (Germany) Revenue: by Geography 2018
  • Figure 27. Ceva Sante Animale (France) Revenue, Net Income and Gross profit
  • Figure 28. Ceva Sante Animale (France) Revenue: by Geography 2018
  • Figure 29. Phibro Animal Health Corp. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Phibro Animal Health Corp. (United States) Revenue: by Geography 2018
  • Figure 31. HIPRA (Spain) Revenue, Net Income and Gross profit
  • Figure 32. HIPRA (Spain) Revenue: by Geography 2018
  • Figure 33. MVP Laboratories Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. MVP Laboratories Inc. (United States) Revenue: by Geography 2018
  • Figure 35. Global Veterinary Vaccine: by Type USD Million (2019-2024)
  • Figure 36. Global Veterinary Vaccine: by Technology USD Million (2019-2024)
  • Figure 37. South America Veterinary Vaccine Share (%), by Country
  • Figure 38. Asia Pacific Veterinary Vaccine Share (%), by Country
  • Figure 39. Europe Veterinary Vaccine Share (%), by Country
  • Figure 40. MEA Veterinary Vaccine Share (%), by Country
  • Figure 41. North America Veterinary Vaccine Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Zoetis Animal Healthcare (United States)
  • Merck & Co. (United States)
  • Virbac SA (France)
  • Hester Biosciences Ltd (India)
  • Elanco (United States)
  • Boehringer Ingelheim Animal Health GmbH (Germany)
  • Ceva Sante Animale (France)
  • Phibro Animal Health Corp. (United States)
  • HIPRA (Spain)
  • MVP Laboratories Inc. (United States)
Additional players considered in the study are as follows:
QianYuanHao Biological Corporation Limited (China) , IZO S.r.l. (Italy) , Intervet International BV (Netherlands) , Indian Immunologicals Limited (India)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation